Hypertension Circulatory System Essential (primary) hypertension
Conditions
Interventions
100,000 units of oral vitamin D3 every two months or placebo.
Total treatment duration: 4 months
Total follow up: 6 months
Sponsors
University of Dundee
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Aged greater than 18 years, either sex 2. Serum 25-hydroxy vitamin D less than 75 nmol/L 3. Office blood pressure (BP) greater than 140/90 mmHg despite three or more anti-hypertensives
Exclusion criteria
Exclusion criteria: 1. Hypertension known to be due to a correctable underlying medical or surgical cause 2. Estimated glomerular filtration rate less than 40 ml/min (by four variable Modification of Diet in Renal Disease [MDRD] equations) 3. Liver function tests (alanine aminotransferase [ALT], bilirubin, alkaline phosphatase) greater than 3 x normal 4. Corrected calcium greater than 2.60 mmol/L or less than 2.15 mmol/L 5. Known metastatic malignancy or sarcoidosis 6. Clinical diagnosis of osteomalacia 7. History of renal calculi 8. Diagnosis of heart failure with left ventricular systolic dysfunction 9. Atrial fibrillation 10. Already taking vitamin D supplements. Consumption of fish oils will not be a contra-indication to enrolment 11. Unable to give written informed consent 12. Pregnant or of childbearing age and not taking reliable contraception
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Office BP, measured at 0, 2, 4 and 6 months | — |
Secondary
| Measure | Time frame |
|---|---|
| LV mass index, measured by cardiac magnetic resonance imaging [MRI] at 0 and 6 months | — |
Countries
United Kingdom
Outcome results
None listed